UP Brothers Prove Sharing Is Overrated, Buys Three Matching Land Rover Defender
The Land Rover Defender has been a spectacular success in the Indian market. It has rapidly become automobile enthusiasts' favourite SUV, hailed as a symbol of wealth and power due to its strong appearance on the road. Auto fanatics would've noted almost every video of the Land Rover Defender attracting eyeballs and humungous views over social media. Now, another video of the vehicle has emerged, where these three brothers taking delivery of three different Defenders on a single day grabbed the attention.
An old clip of these three brothers purchasing the Land Rover Defender together has resurfaced on the internet from the northern state of Uttar Pradesh in India. The video shows three SUVs parked in front of the showroom, all finished in shiny White. The brothers can be seen standing next to the SUVs while also dressed in white and soaking in the laughter, cheers and pride expressed by their friends and family members behind them.
As the video progressed, the vehicles were unveiled before the three brothers posed with their respective Land Rover Defenders and wore a wry smile on their faces, reflecting their excitement and a great sense of pride at owning the luxury vehicle.
The Defender 110 currently has an ex-showroom price of Rs 1.39 Crores in the Indian market, making it among the most expensive automobiles in the country. However, it isn't clear whether the respective SUVs that the brothers posed with were the Defender 110, since the video is from 2024, when there were more variants available in the country. The collective prize of the three SUVs, though, would've easily crossed Rs 3 crores.
The Land Rover's new Defender was introduced in India in 2020. The luxury vehicle was updated to boast of a major variant rejig, which allowed the Defender lineup to be streamlined perfectly by 2025. The Defender continues to excite and entice customers, coming in three body styles: the short wheelbase, standard wheelbase and long wheelbase.
The 2025 range has had minor upgrades inside the cabin, including 14-way heated/cooled electric seats, suede headliner and winged headrests, updated 'PiVi Pro' pack, more storage in the centre console and captain seats for the second row. Apart from that, Defender's V8 engine is now also offered on lower variants: X-Dynamic HSE and X. While the P425 variant produces 420bhp, the P525 V8 makes 517bhp, enabling an acceleration from 0 to 100 kph in 5.2 seconds. The P425 variant took 5.6 seconds for the same.
view comments
First Published:
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
18 minutes ago
- Economic Times
Cisco projects upbeat quarterly revenue as AI fuels networking equipment demand
Reuters Cisco Systems forecast first-quarter revenue above Wall Street estimates on Wednesday, as the artificial intelligence boom boosted demand for its networking equipment from cloud customers. Hyperscale cloud investments are healthy and driving IT infrastructure financing, which sets up a good backdrop for Cisco. "Within the enterprise spending environment, there is incremental spending to beef up the infrastructure to accommodate AI, so that could potentially be another growth driver, especially with Cisco having such a big presence in the traditional enterprise market," Edward Jones analyst David Heger said. Big tech firms such as Microsoft, Amazon and Alphabet are ramping up spending to ease capacity shortages that have limited their ability to meet AI demand, even after several quarters of multi-billion-dollar outlays. Cisco's AI infrastructure orders exceeded $800 million in the fourth quarter, bringing the total for fiscal 2025 to over $2 billion, more than double its original target, CEO Chuck Robbins said on a post-earnings call. The company has not seen any pull-forward in demand for products, but did note a small impact from tariffs in the quarter and during the fiscal year, he added. "We expect the sovereign AI opportunity to build momentum in the second half of fiscal 2026. Cisco will be a core system provider for these significant AI training and inference cluster build outs and integral to their development and eventual hyperscaling." Cisco has partnered with Humain, Saudi Arabia's state-backed AI company, and it will provide digital solutions for Bahrain's government information and telecommunications infrastructure. The company expects revenue to be between $14.65 billion and $14.85 billion for the first quarter, compared with analysts' average estimate of $14.62 billion, according to data compiled by LSEG. Its revenue for the fourth quarter ended July 26 came in at $14.67 billion, compared with estimates of $14.62 billion. Networking product orders grew in the double digits during the quarter, driven by webscale infrastructure, switching, enterprise routing, industrial IoT and servers. Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Tariffs, tantrums, and tech: How Trump's trade drama is keeping Indian IT on tenterhooks Good, bad, ugly: How will higher ethanol in petrol play out for you? As big fat Indian wedding slims to budget, Manyavar loses lustre As 50% US tariff looms, 6 key steps that can safeguard Indian economy Stock Radar: JSPL forms Ascending Triangle pattern on weekly charts, could hit fresh 52-week high soon Nifty and business are different species: 5 small-cap stocks from different sectors with upside potential of up to 30% F&O Radar | Deploy Bear Put Spread in Nifty to play index's negative stance amid volatility Wealth creation: Look beyond the obvious in some things; 10 fertilizer sector companies worth watching
Mint
20 minutes ago
- Mint
BSE SME stock Nisus Finance jumps after Q1 results 2025. Check details
Shares of BSE SME-listed Nisus Finance Services Co. Ltd (NiFCO) gained nearly 2 percent on Thursday, August 14, hitting an intraday high of ₹ 384 after the company reported strong financial results for the quarter ended June 2025 (Q1FY26). The performance reflected sharp year-on-year growth across revenue, profit, and margins, reinforcing investor confidence in the company's strategic direction. The stock has risen 8 percent so far in August after an almost 27 percent rise in July. Before that, it was in the red for 5 straight months between February and June. It shed 14.5 percent in June, 5.75 percent in May, 3.11 percent in April, 14 percent in March, and 11.6 percent in February. Meanwhile, in January, it was flat, up 0.6 percent. In Q1FY26, Nisus Finance posted a net profit of ₹ 16.85 crore, up 103.55 percent year-on-year, while total income surged 91.49 percent to ₹ 28.72 crore. EBITDA rose 83.19 percent to ₹ 21.69 crore, with the net profit margin improving by 348 basis points to 58.68 percent. The company attributed this growth to higher business volumes across both India and UAE markets, coupled with efficient cost management. During the quarter, NiFCO strengthened its first-mover advantage as India's first listed AIF manager, enhancing governance standards and market access. The RESO-1 fund continued to focus on special situations in the real estate sector, particularly complex self-redevelopment projects delivering 21 percent returns. Leveraging its GIFT City structure—among the first licensed for Overseas Portfolio Investment—the company offered Indian investors compliant access to global opportunities. Additionally, its Dubai entity remains the only Indian-promoted fund to secure global lender leverage. NiFCO also advanced its asset tokenization initiatives through a partnership with Toyow, opening up new liquidity channels and expanding institutional investment reach. The company deployed ₹ 24 crore towards fund setup and fundraising expenses, to be amortized over the fund's life. Increased UAE income also lowered the effective tax rate, boosting PAT margin to 59 percent. Amit Goenka, Chairman & Managing Director, said this was the company's strongest first quarter ever, with revenue and profitability seeing substantial year-on-year gains. He highlighted balanced growth between fund management and advisory businesses, alongside strategic investments in urban redevelopment, plans to acquire a leading construction platform, and global partnerships in asset tokenization. 'This has been our strongest first quarter ever, with revenue growing over 91 percent year on year and profitability more than doubling. We have seen strong momentum in both India and the UAE with a good balance between our fund management and advisory businesses. Our operating costs have stayed in line with our expansion plans, which has allowed us to scale efficiently,' Goenka said. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
20 minutes ago
- Business Standard
Pfizer jumps after robust Q1 earnings
Pfizer climbed 5.16% to Rs 5,390.30 after posting a strong performance in the June quarter. On a standalone basis, net profit rose 27.23% year-on-year to Rs 191.75 crore in Q1 FY26 from Rs 150.71 crore in Q1 FY25, but fell 3.3% sequentially from adjusted net profit of Rs 198.33 crore in Q4 FY25. Revenue from operations stood at Rs 603.05 crore, up 7.14% YoY from Rs 562.86 crore and 1.88% higher than Rs 591.91 crore in the March quarter. Profit before tax and exceptional items stood at Rs 259.53 crore in Q1 FY26, up 28.09% YoY and up 2.59% from Rs 252.99 crore in Q4 FY25. Total expenditure rose 1.99% YoY to Rs 393.03 crore from Rs 385.37 crore and was up 7.86% sequentially from Rs 364.41 crore. Cost of material consumed jumped 53.60% YoY to Rs 88.69 crore in Q1 FY26. Pfizer is one of the worlds leading pharmaceutical companies, specialising in four key business categories vaccines, hospitals, internal medicine, and inflammation & immunology.
